Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.

Shield Therapeutics (United Kingdom) a clinical-stage pharmaceutical company focused on inflammatory bowel disease, closed a$12M Series A financing. Participants include Inventages Venture Capital.

N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.

Flexion Therapeutics (Woburn, MA) a clinical-stage biopharma focused on autoimmune disease, ulcerative colitis and tinnitus, closed a $9M Series A financing, bringing the total round to $42M. Participants include Pfizer Venture Investments, Versant Ventures, 5AM Ventures and Sofinnova Ventures.

Lycera Corp (Ann Arbor, MA) a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease, closed a $36M Series A financing. Participants include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.

ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.

  

to top of page...